Deltex Medical Group (DTXMF) Fair Value & Analysis
Healthcare · US · Market cap $181M
Deltex Medical Group
DTXMF · US
Fair value as of: Jun 23, 2026
From 2 valuation models · updated 48 days ago
Below-average quality, and screening another 91% overvalued on our models.
What matters now
- Weak quality (35/100) and above fair value at the same time, the margin of safety is missing on both counts.
- The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jun 23, 2026.
How to read this chart
60‑month range $0.0013 – $0.4917 · the $0.0952 price screens above the $0.0085 fair value. Dashed = 300-day average. As of Jun 23, 2026.
Analysis
Deltex Medical Group (DTXMF) currently trades at $0.0952, while our model-based Fair Value estimate is $0.0085, implying the stock looks roughly 91.1% overvalued today. The Quality Score stands at 35/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).
Over the trailing twelve months, Deltex Medical Group generated revenue of $2.1M at a net margin of -87.4%. Revenue grew 38.4% year over year. It earns a return on equity of -78.2%. Net debt stands at $1.8M. Fundamentals as of Jun 23, 2026
The share trades near its 52-week high, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -22% fair-value upside, at -91%, DTXMF screens richer than that median.
Notify me when DTXMF reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jun 23, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 35 · Market factors (momentum, volatility) 65
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Deltex Medical Group plc, together with its subsidiaries, manufactures, markets, and sells oesophageal doppler and pulse contour analysis and monitoring platform. It offers dopplink, a patient interface cable; and pressurewave, an arterial blood pressure signal under the TrueVue brand. The company also provides oesophageal doppler monitoring systems.
Full company description
Deltex Medical Group plc, together with its subsidiaries, manufactures, markets, and sells oesophageal doppler and pulse contour analysis and monitoring platform. It offers dopplink, a patient interface cable; and pressurewave, an arterial blood pressure signal under the TrueVue brand. The company also provides oesophageal doppler monitoring systems. Deltex Medical Group plc was incorporated in 2000 and is headquartered in Chichester, the United Kingdom.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2020 – FY2024 · reported fiscal years
Deltex Medical Group reported revenue of $2.1M in FY2024 versus $2.4M in FY2020, a compound −3.8%/yr. Reported net income was −$1.8M in FY2024.
DTXMF screens 91% overvalued. Compare with Abbott Laboratories, →
Peer Group
Medical Devices · 352 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Devices median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jun 23, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABT | $100.68 | $74.79 | -26% |
| Stryker Corporation SYK | $316.44 | $186.28 | -41% |
| Medtronic plc MDT | $83.56 | $65.57 | -22% |
| Boston Scientific Corporation BSX | $43.04 | $38.44 | -11% |
| Edwards Lifesciences Corporation EW | $85.73 | $41.02 | -52% |
| Siemens Healthineers AG SHL | €34.59 | €33.87 | -2% |
| Shenzhen Mindray Bio-Medical Electronics Co 300760 | ¥149.43 | ¥147.63 | -1% |
| Shanghai United Imaging Healthcare Co 688271 | ¥109.00 | ¥43.60 | -60% |
| Demant A/S DEMANT | kr 276.60 | kr 161.17 | -42% |
| Getinge AB GETIB | kr 206.80 | kr 192.14 | -7% |
Compare Deltex Medical Group with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Deltex Medical Group (DTXMF) overvalued or undervalued?
What is the fair value of DTXMF?
What is the quality score of DTXMF?
What is the revenue of Deltex Medical Group (DTXMF)?
What is the net profit margin of DTXMF?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Deltex Medical Group and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.